Featured Publications
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer
Kang J, Yu Y, Chen L, Zakeri K, Gelblum D, McBride S, Riaz N, Tsai C, Kriplani A, Hung T, Fetten J, Dunn L, Ho A, Boyle J, Ganly I, Singh B, Sherman E, Pfister D, Wong R, Lee N. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer. CA A Cancer Journal For Clinicians 2022, 73: 164-197. PMID: 36305841, PMCID: PMC9992119, DOI: 10.3322/caac.21758.Peer-Reviewed Original ResearchConceptsTransoral robotic surgeryOropharyngeal cancerDeintensification strategiesHuman papillomavirus-associated oropharyngeal cancerSubstantial long-term morbidityHPV-positive oropharyngeal cancerNational database studyHuman papillomavirus infectionLong-term morbidityThird of patientsDe-escalation trialsLevel I evidenceStandard of careCurrent treatment standardsOptimal patient outcomesDeintensification trialsTreatment deintensificationAdjuvant therapyHPV statusPapillomavirus infectionFavorable prognosisI evidenceMedical oncologyTreatment indicationsCommon cancerLarynx Cancer
Fan D, Kang J, Yu Y, Cahlon O, Riaz N, Lee N. Larynx Cancer. Practical Guides In Radiation Oncology 2022, 45-60. DOI: 10.1007/978-3-030-99590-4_4.Peer-Reviewed Original ResearchPostoperative radiotherapyLarynx cancerEarly stage squamous cell carcinomaOrgan preservation therapyEarly-stage diseaseLymph node metastasisAdvanced larynx cancerSquamous cell carcinomaStandard of careHigh-risk casesPre-treatment evaluationCommon clinical scenariosThin-cut CTPET/CTDefinitive chemoradiotherapyAdvanced diseaseLocoregional recurrencePreservation therapyGlottic larynxNode metastasisSubglottic extensionCell carcinomaLaryngeal cancerPhysical examOrgan preservation
2021
Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center
Kang JJ, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, Wang H, Lobaugh SM, Zhang Z, Lee A, Chen L, Yu Y, Zakeri K, Gelblum DY, Riaz N, McBride SM, Tsai CJ, Cohen MA, Cracchiolo JR, Morris LG, Singh B, Patel S, Ganly I, Boyle JO, Wong RJ, Eng J, Zhi WI, Ng K, Ho AL, Dunn LA, Michel L, Fetten JV, Pfister DG, Lee NY, Sherman EJ. Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center. International Journal Of Cancer 2021, 149: 139-148. PMID: 33586179, PMCID: PMC9380235, DOI: 10.1002/ijc.33518.Peer-Reviewed Original ResearchConceptsTotal cumulative doseHigh-dose cisplatinLocoregional failureOverall survivalOropharyngeal cancerDistant metastasisRegional failureHigh-volume cancer centerLocal failureAlternate dosing schedulesHuman papillomavirus (HPV) statusKarnofsky performance statusCooperative group trialsAdvanced oropharyngeal cancerLarge retrospective reviewStandard of careMultivariable regression modelsDefinitive chemoradiationInduction chemotherapyPerformance statusDosing schedulesTherapy startAdministration dayRetrospective reviewRenal toxicity